{
  "docId": "019de074-559c-76fa-9457-a7d91e9a06c5",
  "docSlug": "15199f0b497c4ef204a0760da27401b3",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 54 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 9,
  "pageCount": 54,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "Includes specific financial terms of the collaboration and regulatory milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-559c-76fa-9457-a7d91e9a06c5/9",
  "deckHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5",
  "deckJsonHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5.json",
  "deckAnchorHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.065,
        "w": 0.595,
        "x": 0.062,
        "y": 0.332
      },
      "kind": "callout",
      "text": "NDA approved December 7, 2021. QIDP, Fast Track and Priority Review Designations",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6b09da1-545e-4792-92e6-ca6ed0d85387",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.115,
        "x": 0.705,
        "y": 0.405
      },
      "kind": "image",
      "text": "ORGANON",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d740e03-c9a3-44af-92a4-be5db7590e34",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.335,
        "w": 0.595,
        "x": 0.074,
        "y": 0.425
      },
      "kind": "list",
      "text": "XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older.* This marks the first FDA-approved product in Daré's portfolio of potential first-in-category development candidates. Organon market access team is meeting with customers now to review XACIATO and obtain competitive coverage in the bacterial vaginosis marketplace. Launch prep activities to continue into 2023. Organon will leverage its established NEXPLANON sales team to accelerate XACIATO uptake at launch. Organon believes there is roughly a 90% overlap of those healthcare providers who prescribe NEXPLANON and who diagnose and treat BV. The strong relationships the sales team has with these providers are expected to enable immediate access as early as day 1. First commercial sale anticipated in 1H2023 in the U.S.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a4754f1-c394-4d98-8f3a-566d6cb5efca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.185,
        "w": 0.255,
        "x": 0.705,
        "y": 0.49
      },
      "kind": "list",
      "text": "The license became effective June 2022. Daré received a $10 million upfront payment from Organon in 3Q 2022. Daré is eligible to receive potential milestone payments of up to $182.5 million and tiered double-digit royalties based on net sales.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de01271a-d25c-4067-9de7-8bb1d527f5b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.375,
        "x": 0.074,
        "y": 0.295
      },
      "kind": "paragraph",
      "text": "XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48556ce9-e6cb-445d-a29e-fd236110810e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.022,
        "w": 0.205,
        "x": 0.705,
        "y": 0.364
      },
      "kind": "paragraph",
      "text": "Commercialization Collaborator",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce573e68-824f-41fb-9d0d-99d9f248fd1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.074,
        "y": 0.8
      },
      "kind": "source-note",
      "text": "*See Full Prescribing Information for the safe and effective use of XACIATO. *See important safety information on slides 20 and 21.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dfd7ba06-fb77-43d3-901a-71a880279e61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.032,
        "w": 0.306,
        "x": 0.347,
        "y": 0.163
      },
      "kind": "title",
      "text": "FDA Approved – XACIATO",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c1f34fc-6348-487e-b4e0-3f6202c1671a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}